



August 1, 2012

Decision: PMPRB-10-D2-SANDOZ
- Merits

IN THE MATTER OF the *Patent Act* R.S.C. 1985, c. P-4,
as amended

AND IN THE MATTER OF
Sandoz Canada Inc.
(the "Respondent")

BOARD ORDER

This proceeding was commenced by a Notice of Application issued by the Board Staff seeking an order pursuant to sections 81 and 88 of the *Patent Act* (the "Act") requiring the Respondent, Sandoz Canada Inc. ("Sandoz") to provide the Board with the information and documents referred to in sections 80, 81 and 88 of the Act and in sections 3, 4, and 5 of the *Patented Medicines Regulations* (the "Regulations").

In accordance with its decision of August 1, 2012, the Panel hereby orders that Sandoz shall file with the Board, on or before October 1, 2012, the information and documents referred to in sections 80, 81 and 88 of the Act and in sections 3, 4, and 5 of the Regulations with respect to each of the following medicines, for the periods during which any of the following patents (as they were referred to in these proceedings) were in force:

- a. Sandoz Cyclosporine (the 827, 091, 509, 792, 018, 963, 150, 775 and 933 patents);
- b. Sandoz Famciclovir (the 503, 376, 383, 462, 268, 756, 238, 505 and 392 patents);
- c. Sandoz Azithromycin (the 639 and 007 patents);
- d. Sandoz Estradiol (the 660, 914, 530, 170, 132 and 384 patents); and
- e. Sandoz Terbinafine (the 229, 341, 957, 651, 971 and 919 patents).

Board Members: Mary Catherine Lindberg
Anne Warner La Forest

Board Counsel: Gordon Cameron

Original signed by

Sylvie Dupont
Secretary of the Board